{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:46:09Z","timestamp":1789908369627,"version":"4.0.1"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. In a phase 1b 3-day monotherapy study, patients treated with a 150-mg dose of GS-5816 had a mean maximal HCV RNA decline of \u22653.3 log\n            <jats:sub>10<\/jats:sub>\n            IU\/ml in GT1a, -1b, -2, -3, and -4. This report characterizes virologic resistance to VEL in these patients. NS5A resistance-associated substitutions (RASs) were detected by deep sequencing (1% cutoff) pretreatment in 22\/70 patients, i.e., 10\/35 (29%) patients with GT1a, 1\/8 (13%) with GT1b, 4\/8 (50.0%) with GT2, 5\/17 (29.4%) with GT3, and 2\/2 (100.0%) with GT4. In GT1a and GT3 patients, pretreatment RASs were associated with a slightly reduced HCV RNA response compared to that of patients without pretreatment RASs; among patients with GT1b, GT2, and GT4, no significant difference in response was observed in those with or without pretreatment RASs. Following treatment, the pattern of emergent RASs was more complex for GT1a than for the other genotypes. In GT1a, substitutions emerged at positions M28, Q30, L31, P32, H58, E92, and Y93, with the most prevalent substitutions at positions Y93, M28, and L31. RASs were observed at two positions in GT1b and GT2 (Y93 and L31), three positions in GT3 (Y93, L31, and E92), and four positions in GT4 (L28, M31, P32L, and Y93). RASs that were present pretreatment persisted through the 48-week follow-up period; however, RASs emerging during treatment were more likely to decline both in prevalence and in frequency within the viral population during follow-up. (This study has been registered at ClinicalTrials.gov under registration no. NCT01740791.)\n          <\/jats:p>","DOI":"10.1128\/aac.00763-16","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T17:07:56Z","timestamp":1467220076000},"page":"5368-5378","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":82,"title":["Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein"],"prefix":"10.1128","volume":"60","author":[{"given":"Eric J.","family":"Lawitz","sequence":"first","affiliation":[{"name":"Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Dvory-Sobol","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Doehle","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela S.","family":"Worth","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McNally","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Brainard","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Link","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Miller","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03432.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.033"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1401726"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20561"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02540.x"},{"key":"e_1_3_3_15_2","volume-title":"EASL 48th Annu Meet","author":"Cheng G","year":"2013","unstructured":"Cheng G, Tian Y, Yu M, Lee Y-J, Gong R, Trejo-Martin A, Peng B, Robinson M, Beran R, Bush C, Chan K, Nash M, Worth A, Yang H, Perry J, Taylor J, Yang C, Paulson M, Delaney W, Link JO. 2013. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier. EASL 48th Annu Meet, Amsterdam, The Netherlands, 24 to 28 April 2013. http:\/\/www.natap.org\/2013\/EASL\/EASL_34.htm."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12435"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2010.090188"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12405"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27934"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","unstructured":"Krishnan P Beyer J Mistry N Koev G Reisch T DeGoey D Kati W Campbell A Williams L Xie W Setze C Molla A Collins C Pilot-Matias T. 2015. In vitro and in vivo antiviral activity and resistance profile of ombitasvir an inhibitor of hepatitis C virus NS5A Antimicrob Agents Chemother 59:979\u2013987. doi:10.1128\/AAC.04226-14.","DOI":"10.1128\/AAC.04226-14"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02777-13"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2729"},{"key":"e_1_3_3_24_2","volume-title":"50th Annu Meet EASL","author":"Black S","year":"2015","unstructured":"Black S, Pak I, Ingravallo P, McMonagle P, Chase R, Shaughnessy M, Hwang P, Haber B, Harrigan PR, Brumme C, Hazuda D, Howe AYM. 2015. Resistance analysis of virologic failures in hepatitis C genotype 1-infected patients treated with grazoprevir + elbasvir \u00b1 ribavirin: the C-WORTHY study, abstr P0891. 50th Annu Meet EASL, Vienna, Austria, 22 to 26 April 2015. http:\/\/www.natap.org\/2015\/EASL\/EASL_107.htm."},{"key":"e_1_3_3_25_2","volume-title":"66th Annu Meet Am Assoc Study Liver Dis","author":"Ng T","year":"2015","unstructured":"Ng T, Pilot-Matias T, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, Asatryan A, Mensa F, Campbell A, Kort J, Collins C. 2015. Analysis of HCV genotype 1 variants detected during monotherapy and combination therapy with next generation HCV direct-acting antiviral agents ABT-493 and ABT-530. 66th Annu Meet Am Assoc Study Liver Dis, 13 to 37 November 2015. http:\/\/www.natap.org\/2015\/AASLD\/AASLD_25.htm."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512614"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02193-12"},{"key":"e_1_3_3_30_2","volume-title":"EASL 47th Annu Meet","author":"Cheng G","year":"2012","unstructured":"Cheng G, Peng B, Corsa A, Yu M, Nash M, Lee YI, Xu Y, Kirschberg T, Tian Y, Taylor J, Link J, Delaney W, IV. 2012. Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885, abstr 1172. EASL 47th Annu Meet, Barcelona, Spain, 18 to 22 April 2012. http:\/\/www.natap.org\/2012\/EASL\/EASL_62.htm."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00289-10"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5424.110"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01382-10"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.08.018"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.09.033"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00307-11"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.029"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00328-07"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24594"},{"key":"e_1_3_3_41_2","volume-title":"IDX719, HCV NS5A inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV infected patients","author":"Mayers D","year":"2012","unstructured":"Mayers D, Vince B, Hill J, Lawitz E, O'Riordan W, Webster L, Gruener D, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bolyai JZ, Zhou XJ. 2012. IDX719, HCV NS5A inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV infected patients. 63rd Annu Meet Am Assoc Study Liver Dis, Boston, MA, 9 to 13 November 2012. http:\/\/www.natap.org\/2013\/HCV\/013113_03.htm."},{"key":"e_1_3_3_42_2","volume-title":"63rd Annu Meet Am Assoc Study Liver Dis","author":"Sulkowski MS","year":"2012","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson IM, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Eley T, Wind-Rotolo M, Huang S-P, Gao M, McPhee F, Sherman E, Hindes R, Symonds WT, Pasquinelli C, Grasela DM, AI444040 Study Group. 2012. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with our without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3. 63rd Annu Meet Am Assoc Study Liver Dis, 9 to 13 November 2012. http:\/\/www.natap.org\/2012\/AASLD\/AASLD_06.htm."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02776-15"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00780-12"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02815-14"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00763-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00763-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:33:35Z","timestamp":1645475615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00763-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1128\/AAC.00763-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.00763-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"2016-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}